As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).

Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.

The 10 therapeutics stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 2.6%.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 15.4% since the latest earnings results.

United Therapeutics (NASDAQ:UTHR)

Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ:UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments.

United Therapeutics reported revenues of $735.9 million, up 19.7% year on year. This print was in line with analysts’ expectations, but overall, it was a slower quarter for the company with a slight miss of analysts’ EPS estimates.

“I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics.

The stock is down 21.4% since reporting and currently trades at $281.52.

Is now the time to buy United Therapeutics? Access our full analysis of the earnings results here, it’s free .

Best Q4: BioMarin Pharmaceutical (NASDAQ:BMRN)

Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.

BioMarin Pharmaceutical reported revenues of $747.3 million, up 15.6% year on year, outperforming analysts’ expectations by 4.8%. The business had a stunning quarter with an impressive beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

BioMarin Pharmaceutical achieved the highest full-year guidance raise among its peers. The stock is down 11.7% since reporting. It currently trades at $58.